Oscotec Inc.

Translating science into medicine
Sign Up
  1. No Image 01Jun

    "ASCO 2018: Genosco/Yuhan Announce Results from Phase 1/2 Study of Lazertinib (YH25448, GNS-1480), a 3rd-Generation EGFR-TKI, in Advanced NSCLC"

  2. No Image 01Jun

    "Global Immune Thrombocytopenia (ITP) Market Insights, Epidemiology, and Forecasts, 2017-2028 : Focus on United States, Germany, Spain, Italy, France, and the United Kingdom, and Japan"

  3. No Image 01Jun

    Abstract 2010 : SKI-G-801, an AXL kinase inhibitor, blocks metastasis and induces anti-tumor immune response in various syngeneic cancer models

  4. No Image 01Jun

    AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications

  5. No Image 01Jun

    G-749, a novel FLT3 Kinase inhibitor, can overcome drug resistance for the treatment of acute myeloid leukemia.

  6. No Image 01Jun

    Genosco gears up for IPO

  7. No Image 01Jun

    Genosco/Yuhan Announce Results from Phase 1/2 Study of YH25448, a 3rd-Generation EGFR-TKI, in Advanced NSCLC to be Presented at ASCO 2018

  8. No Image 01Jun

    INTERVIEW: Oscotec Lays Out Global Ambitions For RA, Cancer Drugs

  9. No Image 01Jun

    IPOs spawn instant billionaires

  10. No Image 01Jun

    Janssen Announces Phase 1 Results for Bispecific Antibody Amivantamab in the treatment of Patients with Advanced Non-Small Cell Lung Cancer Harboring Exon 20 Insertion Mutations

  11. No Image 01Jun

    Korea`s Yuhan Licenses out Lung Cancer Treatment to Janssen Biotech

  12. No Image 01Jun

    Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study

Board Pagination Prev 1 2 3 Next
/ 3
© k2s0o1d6e0s8i2g7n. ALL RIGHTS RESERVED.
Requesting to the server, please wait.